US Drug Recall Register
Class II · Moderate risk Terminated Initiated Nov 1, 2013 (13 years ago)

Tacrolimus 0.02% opth.

Class II — Moderate risk. May cause temporary or reversible harm; serious harm unlikely.

Why it was recalled

Lack of Sterility Assurance: All lots of sterile products compounded by the pharmacy that are not expired due to concerns associated with quality control procedures that present a potential risk to sterility assurance that were observed during a recent FDA inspection.

What was recalled

Tacrolimus 0.02% opth. (H20-based)

Recalling firm
Natures Pharmacy & Compounding Center
Origin
NC, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-1135-2014

What should you do? A recall doesn't always mean your specific bottle is affected - it often applies to certain lots only. Check the lot number on your package against the FDA notice, and talk to your pharmacist before stopping any medication.

Other Tacrolimus recalls

See all
Class I · High risk Ongoing

Prograf

Reason Failed Tablet/Capsule Specifications: Bottles shipped to the USA may contain empty capsules

Astellas Pharma US Inc. NDC 0469-0607-73 D-0211-2025
Class I · High risk Ongoing

Astagraf XL

Reason Failed Tablet/Capsule Specifications: Bottles shipped to the USA may contain empty capsules

Astellas Pharma US Inc. NDC 0469-0647-73 D-0210-2025
Class II · Moderate risk Terminated

Tacrolimus Capsules

Reason Presence of Foreign Tablets/Capsules: One 0.5 mg Tacrolimus capsule found in a bottle of 1 mg Tacrolimus capsules.

Dr. Reddy's Laboratories, Inc. NDC 55111-526-01 D-0219-2024
Class II · Moderate risk Ongoing

Tacrolimus Capsules

Reason Presence of Foreign Tablets/Capsules: Presence of one Tacrolimus 1 mg capsule co-mingled in a bottle containing and labeled as Tacrolimus 0.5 mg capsules.

Dr. Reddy's Laboratories, Inc. NDC 55111-525-01 D-0330-2023
Class II · Moderate risk Terminated

Tacrolimus 0.03% Oph Solution Tacrolimus 0.1%

Reason Lack of Assurance of Sterility: FDA inspection revealed insanitary conditions at the facility.

Pharmacy Innovations D-0237-2023